Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making

This technical report provides a summary of the evidence available at the time of the publication and what will be required in the future to support EU/EEA countries taking decisions on administration of the second dose, following a first dose of Vaxzevria. Since new evidence is being generated continuously and safety monitored on an ongoing basis, it is essential for readers to consider the latest available information.